Lipella Pharmaceuticals
LIPO
LIPO was delisted on the 18th of June, 2025.
3 hedge funds and large institutions have $41.4K invested in Lipella Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.
4% more capital invested
Capital invested by funds: $39.7K → $41.4K (+$1.7K)
0.98% more ownership
Funds ownership: 0.13% → 1.11% (+0.98%)
40% less funds holding
Funds holding: 5 → 3 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$40.4K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$379 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$16.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$11.8K |
| 3 |
HF
HRT Financial
New York
|
-$8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.63K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $41K | +$40.4K | +13,310 | New |
|
|
MCM
2
MAI Capital Management
Independence,
Ohio
| $382 | +$379 | +125 | New |
|
|
3
Bank of America
Charlotte,
North Carolina
| $21 | +$3 | +1 | +17% |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| – | -$16.3K | -4,315 | Closed |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| – | -$11.8K | -3,114 | Closed |
|
|
HF
6
HRT Financial
New York
| – | -$8K | -2,202 | Closed |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | -$3.63K | -962 | Closed |
|
LIPO Hedge Fund Activity: Q4 2024 in Review
3 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q4 2024, worth a combined $41.4K — up 4.3% from $39.7K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LIPO and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $40.4K. The largest seller was Vanguard Group, exiting entirely with an estimated $16.3K sold.
- 3 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q4 2024, down from 5 in Q3 2024.
- Funds reported $41.4K of Lipella Pharmaceuticals stock for Q4 2024, up 4.3% quarter-over-quarter.
- 2 funds opened new Lipella Pharmaceuticals positions in Q4 2024 and 4 closed out, a net change of -2 holders.
- The largest Lipella Pharmaceuticals buyer in Q4 2024 was Virtu Financial, an estimated $40.4K added.
- The largest Lipella Pharmaceuticals seller in Q4 2024 was Vanguard Group, an estimated $16.3K sold.
Based on aggregated 13F filings for Q4 2024.